CN114728054A - 拉沙病毒疫苗 - Google Patents

拉沙病毒疫苗 Download PDF

Info

Publication number
CN114728054A
CN114728054A CN202080071104.5A CN202080071104A CN114728054A CN 114728054 A CN114728054 A CN 114728054A CN 202080071104 A CN202080071104 A CN 202080071104A CN 114728054 A CN114728054 A CN 114728054A
Authority
CN
China
Prior art keywords
leu
gly
sequence
protein
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080071104.5A
Other languages
English (en)
Chinese (zh)
Inventor
K·达迈尔
V·莱门斯
J·奈茨
L·桑切斯费利佩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Publication of CN114728054A publication Critical patent/CN114728054A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080071104.5A 2019-09-13 2020-09-11 拉沙病毒疫苗 Pending CN114728054A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19197202.5 2019-09-13
EP19197202 2019-09-13
PCT/EP2020/075541 WO2021048402A1 (en) 2019-09-13 2020-09-11 Lassavirus vaccines

Publications (1)

Publication Number Publication Date
CN114728054A true CN114728054A (zh) 2022-07-08

Family

ID=68137784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080071104.5A Pending CN114728054A (zh) 2019-09-13 2020-09-11 拉沙病毒疫苗

Country Status (8)

Country Link
US (1) US12558410B2 (https=)
EP (1) EP4041300A1 (https=)
JP (1) JP7663250B2 (https=)
CN (1) CN114728054A (https=)
AU (1) AU2020346382A1 (https=)
BR (1) BR112022004378A2 (https=)
WO (1) WO2021048402A1 (https=)
ZA (1) ZA202203730B (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190276500A1 (en) * 2016-08-10 2019-09-12 Fundação Oswaldo Cruz Heterologous expression cassette, dna construct and vaccine composition to immunize against flavivirus and/or other pathogens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042014A1 (en) 2003-10-29 2005-05-12 The University Of Queensland West nile virus vaccine
JP5779352B2 (ja) * 2008-03-14 2015-09-16 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
GB201307528D0 (en) 2013-04-26 2013-06-12 Univ Leuven Kath Bacterial artificial chromosomes
WO2019018501A1 (en) 2017-07-18 2019-01-24 Geovax Inc. COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190276500A1 (en) * 2016-08-10 2019-09-12 Fundação Oswaldo Cruz Heterologous expression cassette, dna construct and vaccine composition to immunize against flavivirus and/or other pathogens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PETER J. BREDENBEEK等: "A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins", 《VIROLOGY》, vol. 345, no. 2, 18 January 2006 (2006-01-18), pages 299 - 304 *
XIAOHONG JIANG等: "Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs", 《VACCINE》, vol. 29, no. 6, 8 December 2010 (2010-12-08), pages 1248 - 1257, XP028175836, DOI: 10.1016/j.vaccine.2010.11.079 *

Also Published As

Publication number Publication date
BR112022004378A2 (pt) 2022-06-07
EP4041300A1 (en) 2022-08-17
US20220378903A1 (en) 2022-12-01
JP2022547695A (ja) 2022-11-15
ZA202203730B (en) 2025-09-25
US12558410B2 (en) 2026-02-24
JP7663250B2 (ja) 2025-04-16
AU2020346382A1 (en) 2022-04-21
WO2021048402A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
US11638750B2 (en) Methods for generating a Zikv immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 protein
US20250099568A1 (en) Chimeric Flavivirus Lyssavirus Vaccines
MX2010010034A (es) Vacunas de flavivirus defectuosas en replicacion y vectores de vacunas.
WO2014093602A1 (en) Compositions and methods for treating and preventing hepatitis c virus infection
JP7663250B2 (ja) ラッサウイルスワクチン
US12545709B2 (en) Chimeric filovirus vaccines
OA20740A (en) Lassavirus vaccines.
RU2816136C2 (ru) Химерные вакцины на основе вирусов родов flavivirus и lyssavirus
CN114072168A (zh) 嵌合寨卡-日本脑炎病毒
OA20659A (en) Chimeric filovirus vaccines.
US11351240B2 (en) Chimeric yellow fever ZIKA virus strain
CN120359046A (zh) 对鲑科鱼类进行疫苗施用的方法
AU2002360315B2 (en) Thymosin augmentation of genetic immunization
NZ532863A (en) Thymosin augmentation of genetic immunization for the treatment of hepatitis C
US20160215023A1 (en) Simple vaccines from dna launched suicidal flaviviruses
HK1162306B (en) Replication-defective flavivirus vaccines and vaccine vectors
WO2004082712A1 (fr) Vaccin divalent
AU2002360315A1 (en) Thymosin augmentation of genetic immunization

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220708